Trasylol^®

We have been involved with representing those injured from the use of the drug Trasylol^®. Trasylol^® is a drug manufactured by Bayer Pharmaceutical Corporation, a part of Bayer HealthCare AG and a subsidiary of Bayer AG. Originally, the drug was approved in 1993 by FDA for the use in reducing blood loss and blood transfusions during surgery. Trasylol is given to patients intravenously along with other medicines so that most people do not even know that they are receiving it. Doctors do not need special permission to administer it. 

According to a report in The New England Journal of Medicine, Trasylol^® (aprotinin) has been found to increase the risk of heart attack, stroke and kidney failure.  The study suggested that two other drugs are as effective in preventing blood loss and are safer and cheaper than Trasylol^®.   The study involved over 4000 heart surgery patients who received Trasylol^®, aminocaproic acid, tranexamic acid or no agent.  Of those, 3,013 patients underwent surgery to open a blocked coronary artery and 1,361 underwent more complex procedures.  The study found that those in the first group that were given Trasylol had significantly increased risk of heart attack, stroke and kidney failure compared with patients who received no treatment. Trasylol was associated with an increased risk of renal failure only with respect to the second group.  Aminocaproic acid and tranexamic acid were both seen to reduce bleeding similar to Trasylol without the increased risks of heart attack, stroke and kidney failure.

Bayer issued a statement saying that it believes Trasylol^® is a safe and effective treatment. But on November 5, 2007, Bayer suspended the global marketing of Trasylol^® after a request from the FDA to do so. That request followed a Canadian study that suggested an increased risk of death following use of the product.

If you or a loved one believes that they have been injured by Trasylol^®, please call us for a free consultation.